Ajai Chari
MD
Professor
👥Biography 个人简介
Ajai Chari has contributed to the development of bispecific antibody therapy for myeloma, including teclistamab (BCMA x CD3) and talquetamab (GPRC5D x CD3) — off-the-shelf T cell-engaging bispecific antibodies that achieve deep responses in relapsed/refractory myeloma without the complexity and delay of manufacturing patient-specific CAR-T cells. These agents are transforming the relapsed myeloma treatment landscape.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ajai Chari 的研究动态
Follow Ajai Chari's research updates
留下邮箱，当我们发布与 Ajai Chari（UCSF）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment